Jaguar Animal Health (NASDAQ:JAGX) Announces Earnings Results, Beats Estimates By $135.50 EPS

Jaguar Animal Health (NASDAQ:JAGX) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50, FiscalAI reports. The firm had revenue of $20.27 million during the quarter, compared to analysts’ expectations of $4.21 million. Jaguar Animal Health had a negative net margin of 169.04% and a negative return on equity of 1,194.94%.

Jaguar Animal Health Stock Performance

Shares of JAGX opened at $3.47 on Friday. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.29 and a current ratio of 0.50. Jaguar Animal Health has a twelve month low of $2.53 and a twelve month high of $171.50. The firm’s 50 day moving average price is $11.16 and its two-hundred day moving average price is $27.30. The firm has a market cap of $1.28 million, a P/E ratio of 0.00 and a beta of 0.01.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JAGX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a report on Sunday, May 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.